A detailed history of Jpmorgan Chase & CO transactions in Rallybio Corp stock. As of the latest transaction made, Jpmorgan Chase & CO holds 882 shares of RLYB stock, worth $899. This represents 0.0% of its overall portfolio holdings.

Number of Shares
882
Previous 14,592 93.96%
Holding current value
$899
Previous $26,000 96.15%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$1.34 - $2.98 $18,371 - $40,855
-13,710 Reduced 93.96%
882 $1,000
Q1 2024

May 10, 2024

SELL
$1.25 - $2.4 $6,725 - $12,912
-5,380 Reduced 26.94%
14,592 $26,000
Q4 2023

Feb 12, 2024

SELL
$1.91 - $4.39 $3 - $8
-2 Reduced 0.01%
19,972 $47,000
Q3 2023

Nov 14, 2023

SELL
$3.37 - $6.16 $15,869 - $29,007
-4,709 Reduced 19.08%
19,974 $67,000
Q2 2023

Aug 11, 2023

SELL
$4.31 - $8.89 $28,764 - $59,331
-6,674 Reduced 21.28%
24,683 $139,000
Q1 2023

May 18, 2023

BUY
$4.37 - $8.75 $62,984 - $126,113
14,413 Added 85.06%
31,357 $179,000
Q1 2023

May 11, 2023

BUY
$4.37 - $8.75 $24,402 - $48,860
5,584 Added 49.15%
16,944 $96,000
Q4 2022

Feb 13, 2023

BUY
$4.67 - $14.86 $2,629 - $8,366
563 Added 5.21%
11,360 $74,000
Q3 2022

Nov 14, 2022

BUY
$7.54 - $14.56 $5,941 - $11,473
788 Added 7.87%
10,797 $156,000
Q2 2022

Aug 11, 2022

SELL
$6.26 - $13.65 $14,804 - $32,282
-2,365 Reduced 19.11%
10,009 $75,000
Q1 2022

May 11, 2022

SELL
$6.91 - $15.04 $2.18 Million - $4.75 Million
-315,840 Reduced 96.23%
12,374 $86,000
Q4 2021

Feb 10, 2022

BUY
$9.3 - $19.91 $2.54 Million - $5.44 Million
273,209 Added 496.7%
328,214 $3.13 Million
Q3 2021

Nov 12, 2021

BUY
$10.83 - $23.4 $595,704 - $1.29 Million
55,005 New
55,005 $967,000

Others Institutions Holding RLYB

About Rallybio Corp


  • Ticker RLYB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,132,000
  • Market Cap $32.8M
  • Description
  • Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of feta...
More about RLYB
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.